You just read:

Biohaven Receives FDA May Proceed Letter to Begin Phase 2 Trial of Intranasal Vazegepant to Treat Lung Inflammation After COVID-19 Infection

News provided by

Biohaven Pharmaceutical Holding Company Ltd.

Apr 09, 2020, 07:30 ET